Pfizer has filed a lawsuit against Novo Nordisk and Metsera in an attempt to force through its takeover of the weight-loss drug developer and prevent Novo Nordisk from taking its rival bid forward.

CSL has said that with flu jab rates in the US down between 12% and 14% this year, it has decided to delay the planned spinout of its Seqirus vaccines business and cut its profit forecast for the ...

MSD and Eisai's combination of Keytruda and Lenvima has become a driver of growth for both products, but their efforts to extend the regimen into liver cancer have hit a hurdle. The two partners said ...

Shares in Eli Lilly were rising this morning after the company celebrated a massive 54% increase in its third-quarter revenues to $17.6 billion, driven by its medicines for diabetes and obesity.

George Medicines' recently-approved high blood pressure therapy Widaplik could offer a desperately needed new treatment for patients with intracerebral haemorrhage (ICH), the most severe form of ...

AstraZeneca's baxdrostat has hit the mark in another phase 3 trial involving people who struggle to control their blood pressure with current therapies, keeping the would-be blockbuster on track for ...

Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics – a developer of in vivo cell therapies – for $1.5 billion in cash. Cambridge, Massachusetts-based Orbital is ...

Kailera Therapeutics has raised an eye-watering $600 million in Series B financing to take its lead drug for weight loss into pivotal trials, in a further sign of the insatiable investor appetite for ...

So it was that pharmaphorum sat down with Jan Kirsten, global head of the rare tumour business for SpringWorks Therapeutics – a healthcare company of Merck KGaA – to discuss mirdametinib’s application ...

Faced with soaring demand for leucovorin for use in children with autism, the American Academy of Paediatrics (AAP) has said ...

Final draft guidance on NHS use of the drug marks a "significant shift" from NICE's 2021 decision on the drug as a first-line ...

As drug development becomes more complex, so do the demands for accurate, reproducible bioanalytical data to prove their ...